Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALNY NASDAQ:QDEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNYAlnylam Pharmaceuticals$281.26-2.4%$295.45$273.11▼$495.55$38.46B0.271.50 million shs1.09 million shsQDELQuidelOrtho$17.66-1.3%$13.88$9.92▼$35.58$1.22B0.691.60 million shs784,679 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNYAlnylam Pharmaceuticals-2.36%-12.54%-0.56%-15.64%-10.92%QDELQuidelOrtho-1.29%+3.88%+24.98%+0.97%-38.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNYAlnylam Pharmaceuticals$281.26-2.4%$295.45$273.11▼$495.55$38.46B0.271.50 million shs1.09 million shsQDELQuidelOrtho$17.66-1.3%$13.88$9.92▼$35.58$1.22B0.691.60 million shs784,679 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNYAlnylam Pharmaceuticals-2.36%-12.54%-0.56%-15.64%-10.92%QDELQuidelOrtho-1.29%+3.88%+24.98%+0.97%-38.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALNYAlnylam Pharmaceuticals 2.85Moderate Buy$455.3161.88% UpsideQDELQuidelOrtho 1.67Reduce$13.63-22.85% DownsideCurrent Analyst Ratings BreakdownLatest QDEL and ALNY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2026ALNYAlnylam Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$460.00 ➝ $410.007/13/2026ALNYAlnylam Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$505.00 ➝ $410.007/13/2026ALNYAlnylam Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$470.00 ➝ $485.007/10/2026ALNYAlnylam Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$370.00 ➝ $400.007/8/2026QDELQuidelOrtho CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$13.00 ➝ $18.007/1/2026QDELQuidelOrtho JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderweight$11.00 ➝ $12.006/29/2026QDELQuidelOrtho Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold6/29/2026ALNYAlnylam Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$510.00 ➝ $470.006/15/2026QDELQuidelOrtho Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold6/4/2026ALNYAlnylam Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$510.005/19/2026ALNYAlnylam Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$380.00(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALNYAlnylam Pharmaceuticals$3.71B10.11$2.73 per share103.02$5.97 per share47.11QDELQuidelOrtho$2.73B0.44$18.79 per share0.94$28.27 per share0.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALNYAlnylam Pharmaceuticals$313.75M$3.6676.8527.82N/A11.72%85.76%10.32%7/30/2026 (Estimated)QDELQuidelOrtho-$1.13B-$17.82N/A7.51N/A-45.57%4.25%1.56%7/29/2026 (Estimated)Latest QDEL and ALNY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2026Q2 2026ALNYAlnylam Pharmaceuticals$1.61N/AN/AN/A$1.32 billionN/A7/29/2026Q2 2026QDELQuidelOrtho-$0.04N/AN/AN/A$619.54 millionN/A5/5/2026Q1 2026QDELQuidelOrtho$0.37-$0.04-$0.41-$1.35$665.23 million$619.80 million4/30/2026Q1 2026ALNYAlnylam Pharmaceuticals$0.8720$1.99+$1.1180$1.51$1.12 billion$1.17 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALNYAlnylam PharmaceuticalsN/AN/AN/AN/AN/AQDELQuidelOrthoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALNYAlnylam Pharmaceuticals0.943.133.06QDELQuidelOrtho1.331.430.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALNYAlnylam Pharmaceuticals92.97%QDELQuidelOrtho99.00%Insider OwnershipCompanyInsider OwnershipALNYAlnylam Pharmaceuticals0.86%QDELQuidelOrtho1.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALNYAlnylam Pharmaceuticals2,770133.51 million132.37 millionOptionableQDELQuidelOrtho6,50068.19 million67.44 millionOptionableQDEL and ALNY HeadlinesRecent News About These CompaniesQuidelOrtho (NASDAQ:QDEL) Stock Price Up 6.1% - Here's WhyJuly 12 at 11:23 AM | americanbankingnews.comQuidelOrtho (NASDAQ:QDEL) Trading 6.1% Higher - Time to Buy?July 10, 2026 | marketbeat.comSpotting winners: QuidelOrtho (NASDAQ:QDEL) and healthcare equipment and supplies stocks in Q1July 8, 2026 | msn.comQuidelOrtho: Too Much Uncertainty Around Earnings Keeping Short-Interest ElevatedJuly 8, 2026 | seekingalpha.comQuidelOrtho Corporation (NASDAQ:QDEL) Given Average Rating of "Reduce" by AnalystsJuly 4, 2026 | americanbankingnews.comQuidelOrtho Stock Short Interest Report | NASDAQ:QDEL | BenzingaJune 30, 2026 | benzinga.comQuidelOrtho to Report Second Quarter 2024 Financial ResultsJune 30, 2026 | businesswire.comDoes QuidelOrtho's (QDEL) Index Exit and New CFO Hint at a Shift in Growth Identity?June 30, 2026 | finance.yahoo.comQuidelOrtho (QDEL) Moves 32.2% Higher: Will This Strength Last?June 30, 2026 | zacks.comQDEL Stock Eyes Best Day In Over A Year — Point-Of-Care Sale Talks Ignite RallyJune 29, 2026 | finance.yahoo.comQuidelOrtho plans to sell testing unit for $1.5B: FTJune 27, 2026 | msn.comQDEL Q1 Deep Dive: Softer Respiratory Demand and China Headwinds Drive Guidance ResetJune 25, 2026 | theglobeandmail.comQuidelOrtho Corporation (NASDAQ:QDEL) Q4 2024 Earnings Call TranscriptJune 25, 2026 | msn.comQuidelOrtho Names New Chief Financial Officer, Plans TransitionJune 23, 2026 | tipranks.comQuidelOrtho Appoints Micah Young as Chief Financial OfficerJune 23, 2026 | prnewswire.comReasons to Retain QuidelOrtho Stock in Your Portfolio for NowJune 17, 2026 | zacks.comIs QuidelOrtho Corp (QDEL) a Bargain After 3.3% Drop? GF Value Says UndervaluedJune 16, 2026 | gurufocus.comQuidelOrtho Shareholders Approve Directors, Pay and AuditorJune 16, 2026 | tipranks.comIs the Options Market Predicting a Spike in QuidelOrtho Stock?June 12, 2026 | zacks.com1 Stock Under $50 with Exciting Potential and 2 Facing ChallengesJune 9, 2026 | finance.yahoo.comA Look At QuidelOrtho (QDEL) Valuation After Recent Share Price Rebound And Longer Term WeaknessJune 8, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQDEL and ALNY Company DescriptionsAlnylam Pharmaceuticals NASDAQ:ALNY$281.26 -6.80 (-2.36%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$283.27 +2.01 (+0.71%) As of 07/14/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.QuidelOrtho NASDAQ:QDEL$17.66 -0.23 (-1.29%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$17.66 0.00 (-0.03%) As of 07/14/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
